Design, Structure Optimization, and Preclinical Evaluation of <sup>188</sup>Re-Labeled FAPI for Targeted Radionuclide Therapy
Mengxin Xu(Peking University), Zhibo Liu(First Affiliated Hospital of Zhengzhou University), Jin Du(China University of Petroleum, East China), Rui Wang, Zhu Li(Tianjin Infectious Diseases Hospital), Yü Liu(Hebei University of Chinese Medicine), Junyi Chen(Peking University), Jie Cai(Wuhan University), Changlun Wang(Peking University), Hanbo Song(China Institute of Atomic Energy), Xi‐Yang Cui(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 6
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Deciphering the Modulation Essence of p Bands in Co-Based Compounds on Li-S Chemistry
|Joule|2018|540
A corrosion-resistant RuMoNi catalyst for efficient and long-lasting seawater oxidation and anion exchange membrane electrolyzer
|Nature Communications|2023|483